| United States | 2,000 mgreference, not a law · 19%Comparison note2,500 mg (ages 19–50) · 2,000 mg (51 and older) | 3,000 mgreference, not a law · 6%Comparison note4,000 mg (ages 19–70) · 3,000 mg (71 and older) | 350 mgreference, not a law · 4% | —not on file |
| Austria | 800 mgrecommendation · 49% | 800 mgrecommendation · 22% | 375 mgrecommendation · 3% | 500 mgrecommendation · 25% |
| Belgium | 1,600 mglaw · 24% | —not on file | 450 mglaw · 3% | 6,000 mglaw · 2% |
| Croatia | 1,500 mglaw · 26% | 1,400 mglaw · 12% | 375 mglaw · 3% | 2,000 mglaw · 6% |
| Cyprus | 1,500 mglaw · 26% | 1,100 mglaw · 16% | 300 mglaw · 4% | —not on file |
| Denmark | 1,327 mgrecommendation · 29% | —not on file | 233 mgrecommendation · 6% | 3,000 mgrecommendation · 4% |
| EAEU | 2,500 mglaw · 16% | 1,600 mglaw · 11% | 800 mglaw · 2% | 3,500 mglaw · 4% |
| Estonia | 2,500 mgrecommendation · 16% | 3,000 mgrecommendation · 6% | 250 mgrecommendation · 5% | —not on file |
| Finland | 2,500 mgrecommendation · 16% | —not on file | 250 mgrecommendation · 5% | —not on file |
| France | 800 mglaw · 49% | 450 mglaw · 38% | 300 mglaw · 4% | 80 mglaw · 156% · above |
| Germany | 500 mgrecommendation · 78% | 0 mgrecommendation · not compared · above | 250 mgrecommendation · 5% | 500 mgrecommendation · 25% |
| Ireland | 2,500 mgrecommendation · 16% | —not on file | 250 mgrecommendation · 5% | —not on file |
| Italy | 1,200 mgrecommendation · 32% | —not on file | 450 mgrecommendation · 3% | —not on file |
| Luxembourg | 1,600 mglaw · 24% | 1,400 mglaw · 12% | 562.5 mglaw · 2% | 3,360 mglaw · 4% |
| Malta | 1,500 mgrecommendation · 26% | 250 mgrecommendation · 69% | 400 mgrecommendation · 3% | 3,700 mgrecommendation · 3% |
| Norway | 705 mglaw · 55% | —not on file | 350 mglaw · 4% | —not on file |
| Poland | 1,500 mgrecommendation · 26% | 450 mgrecommendation · 38% | 400 mgrecommendation · 3% | 1,500 mgrecommendation · 8% |
| Switzerland | 750 mglaw · 52% | —not on file | 375 mglaw · 3% | 2,250 mglaw · 6% |